The Influence of Early and Continuous Exposure of Infants to Cow's Milk Formula on the Prevention of Milk Allergy

Sponsor
Meir Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT02785679
Collaborator
Schneider Children's Hospital (Other)
2,500
1
4
45.4
55.1

Study Details

Study Description

Brief Summary

Cow's milk protein (CMP) allergy is one of the most common food allergies and potentially a fatal one. Early feeding with CMP has been considered in the past as a risk factor for development of CMP allergy in high risk infants. Although other studies argue with this assumption and suggest early exposure to CMP might be protective against atopic dermatitis and CMP allergy. A cohort study that first introduction of CMP after 15-30 days of age, raised the risk for CMP allergy.The aim of this study is to investigate if early and continuous exposure to CMF will decrease CMP allergy rate.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: cow's milk formula
N/A

Detailed Description

Background: Cow's milk protein (CMP) allergy is one of the most common food allergies and potentially a fatal one. The incidence of milk allergy is 1.5-3% in the first year of life, but only 60% of the reactions are IgE mediated. CMP allergy tends to resolve in approximately 45-50% of the infants at 1 year of age, in 60-75% at the age of 2, and 85-90% at 3 years. The range for IgE mediated CMP allergy is 29-76%. A recent study suggested that the natural history of CMP allergy might have changed over time, with slower rates of resolution and a higher proportion of children with disease persisting into adolescence and adulthood. In the past it has been described that there is more incidence of CMP allergy in children from families with positive history of allergy. Early feeding with CMP has been considered in the past as a risk factor for development of CMP allergy in high risk infants. Although other studies argue with this assumption and suggest early exposure to CMP might be protective against atopic dermatitis and CMP allergy. A cohort study that first introduction of CMP after 15-30 days of age, raised the risk for CMP allergy. A recent study on peanut allergy found that continuous early exposure to peanut dramatically decreased the incidence of peanut allergy. The research in the field of food allergy and especially in CMP allergy is very alert those days. But as far as the investigators knowledge, there are no prospective studies from the first days of life that examined the influence of early and continuous exposure to cow's milk formula (CMF) on CMP allergy. The existing data related to CMP allergy is controversial and inconclusive. Thus, no one can rely on it to establish clear recommendations for parents when is the best time to combine CMF in the infants diet. Working hypothesis and aims: The aim of the study is to investigate if early and continuous exposure to CMF will decrease CMP allergy rate. The investigators assumption is that the rate of CMP allergy in the intervention groups and in infants who are only feed by CMF, will be lower than in the group of infants who are exclusively breast feed. Methods: Recruitment of 2,500 infants from first day of life and divide the participants into 4 groups: 1. Exclusive breast feeding. 2. Exclusive CMF feeding. 3. Breast feeding with 20 cc of CMF per day. 4. Breast feeding with one meal per day of CMF. The mother will complete a survey questionnaire before the labor. Infants will be followed for 1 year. During this follow-up period -the participants will be examined by an allergologist at the age of 2 month and 1 year. In between, the infants will be followed by a phone questionnaire once in a month. Specific CM IgE analysis from umbilical cord blood and skin test at 2 month of age will be performed. Inclusion criteria - Term and near term newborns (gestational age of at least 36 weeks), normal birth weight, normal perinatal follow-up and without congenital defects. Expected results: The rate of CMP allergy in the intervention groups and in the group on exclusively CMF feeding will be lower than in the group on exclusive breast feeding. Importance: If the investigators will be able to prove the study hypothesis (and even if not), it will have a significant influence on the diet recommendations for infants. Probable implications to Medicine: If the investigators will get the expected results, the recommendations that exist today for infant's feeding can be changed.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2500 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
The Influence of Early and Continuous Exposure of Infants to Cow's Milk Formula on the Prevention of Milk Allergy
Actual Study Start Date :
Mar 20, 2018
Anticipated Primary Completion Date :
Aug 31, 2021
Anticipated Study Completion Date :
Dec 31, 2021

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Exclusive breast feeding

Exclusive breast feeding

No Intervention: Exclusive CMF feeding

Exclusive CMF feeding

Active Comparator: Breast feeding with small amount of CMF

Breast feeding with addition (as intervention) of 20 cc of cow's milk formula (CMF) per day

Dietary Supplement: cow's milk formula
addition of cow's milk formula in two different dosage - one only 20ml per day and one group a full meal per day

Active Comparator: Breast feeding with one meal of CMF

Breast feeding with addition (as intervention) of one meal per day of cow's milk formula (CMF)

Dietary Supplement: cow's milk formula
addition of cow's milk formula in two different dosage - one only 20ml per day and one group a full meal per day

Outcome Measures

Primary Outcome Measures

  1. The incidence of cow's milk allergy in the intervention groups [1 year]

    Measure the rate of cow's milk allergy infants in each group and compare the rate of allergy between the groups.

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Hours to 2 Days
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Term and near term newborns (gestational age of at least 36 weeks)

  • normal birth weight

  • normal perinatal follow-up (physiological neonatal jaundice is not an exclusion criteria)

  • without congenital defects

Exclusion Criteria:
  • Preterm newborns

  • Congenital defects

  • Newborn suffering from acute event

Contacts and Locations

Locations

Site City State Country Postal Code
1 Meir medical center Kfar Saba Israel

Sponsors and Collaborators

  • Meir Medical Center
  • Schneider Children's Hospital

Investigators

  • Study Director: Ronit Confino- Cohen, MD, allergy and immunology unit, MeirMc

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Meir Medical Center
ClinicalTrials.gov Identifier:
NCT02785679
Other Study ID Numbers:
  • 011-16-MMC
First Posted:
May 30, 2016
Last Update Posted:
Apr 14, 2021
Last Verified:
Apr 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Meir Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 14, 2021